Salute e Benessere

Lesaffre strengthens its Research, Development & Innovation (RD&I) with the…

"At Lesaffre, we are driven by an unwavering belief in the infinite possibilities of fermentation," says Brice-Audren Riché, CEO of Lesaffre. "Powered by the incredible potential of microorganisms, we see fermentation as a transformative solution to nourish a growing global population in a safer, healthier, and more sustainable way. As a leader in bioengineering and bioprocesses, we naturally place research, development, and innovation at the heart of our success. Our strong…
PR Newswire
07/10/2024

International Experts Highlight Pleiotropic Benefits of Vitamin D Beyond Bone…

Extraskeletal Vitamin D – The experts' opinion on this point is unanimous: vitamin D is not just involved in the skeletal system, which is the current focus of most guidelines and consensus statements issued by the scientific community. «Vitamin D functions as a hormone: it is only partially taken in through food and is produced by our body mainly through the cutaneous synthesis of cholecalciferol in response to exposure to solar radiation. And it has a pleiotropic effect, i.e. it can act on…
PR Newswire
07/10/2024

Mérieux NutriSciences Enters Agreement to Acquire Worldwide Food Testing…

Building on Mérieux NutriSciences' existing worldwide presence and reputation for delivering high-value, science-based solutions to its customers, this acquisition will enhance its global footprint, extending its operations to 32 countries, and doubling its presence in Canada and the Asia Pacific region. Building on Mérieux NutriSciences' existing worldwide presence and reputation for delivering high-value, science-based solutions to its customers, this acquisition will enhance its global...
PR Newswire
07/10/2024

IMU Biosciences joins ground-breaking UK research consortium investigating…

PRESS RELEASE IMU Biosciences joins ground-breaking UK research consortium investigating patient response tocancer immunotherapiesConsortium includes leading research institutions, NHS Trusts and industry members and aims to make pioneering immunotherapies safer and more effectiveLondon, UK, 7 October 2024– IMU Biosciences (or “the Company”), a biotechnology company pioneering systems-level immune profiling with AI to drive breakthroughs in precision medicine, is pleased to...
Nasdaq GlobeNewswire
07/10/2024

Medinol Announces Successful First-in-Human Implantation of ChampioNIR…

"We were impressed with ChampioNIR's deliverability and its straightforward deployment", said Prof. Gerard S Goh, Head of Interventional Radiology at The Alfred Hospital. "The Frictionless Deployment Mechanism made the precise positioning of the stent very straightforward". "We were impressed with ChampioNIR's deliverability and its straightforward deployment", said Prof. Gerard S Goh, Head of Interventional Radiology at The Alfred Hospital. "The Frictionless…
PR Newswire
07/10/2024

BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line…

The Phase 1b part of the study evaluated three escalating doses of BerGenBio's selective AXL inhibitor bemcentinib in combination with standard chemo-immunotherapy (CIT), doublet chemotherapy and pembrolizumab, Keytruda®, for the 1L treatment of advanced/metastatic NSCLC patients. The primary endpoint was the assessment of the safety profile of the combination in NSCLC patients regardless of their STK11 mutational status. The Phase1bpart of the study evaluated three escalating doses of...
PR Newswire
07/10/2024

BioSenic S.A. : Transparency notification received from ABO Infinium Americas…

REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, October 7, 2024, 7:00 CEST –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received a transparency notification from ABO Infinium Americas OpCo LTD. The details of the transparency notification are set out below and the full text of the...
Nasdaq GlobeNewswire
07/10/2024

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic…

Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024.Mr. Nodelman replaces Mr. Dan G. Baker who stepped down on October 6, 2024. The addition of Mr. Nodelman marks an important step in Galapagos' ongoing efforts to engage with shareholders and continue to execute on ourForward, Faster...
Nasdaq GlobeNewswire
07/10/2024

Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda

[Caption] Sabin Vaccine Institute delivered 700 doses of its Marburg vaccine to Rwanda on Oct. 5, 2024. WASHINGTON, Oct.05, 2024(GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has provided its investigational Marburg vaccine to Rwanda to support the ongoing outbreak response. The initial shipment of approximately 700 vaccine doses will be used in a trial targeting frontline workers, including healthcare professionals who have been hardest hit by the deadly virus. Sabin has entered...
Nasdaq GlobeNewswire
06/10/2024

BIOVAXYS ANNOUNCES CLOSING OF FIFTH TRANCHE OF PRIVATE PLACEMENT

The Company intends to use the proceeds of the Private Placement for general working capital purposes, including enabling the Company to fund and advance its business plans in regard to its successful recent acquisition of the entire portfolio of discovery, preclinical and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX™ immune educating platform technology, developed by the former Canadian biotechnology…
PR Newswire
05/10/2024

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 4, 2024 –Genmab A/S(Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Baillie Gifford & Co has informed us that, as of October 3, 2024, Baillie Gifford & Co held the voting rights to 3,301,530 shares in Genmab A/S, which amounts to 4.99% of the share capital and voting rights in Genmab A/S. About Genmab Genmab is an...
Nasdaq GlobeNewswire
04/10/2024

Bicomponent Fiber Market Size to Grow USD 6045.6 Million by 2030 at a CAGR of…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-36C357/Global_Bicomponent_Fiber_Market Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-36C357/Global_Bicomponent_Fiber_Market Major Factor : The bicomponent fiber market is experiencing robust growth due to increasing demand across various industries, including textiles, hygiene products, and automotive applications. Bicomponent fibers consist of two polymers with different properties,...
PR Newswire
04/10/2024

Peritoneal Dialysis Market to Hit USD 12.70 Billion by 2029 with 5.8% CAGR |…

Browse in-depth TOC on "Peritoneal Dialysis Market" Browse in-depth TOC on "Peritoneal Dialysis Market" 241 - Tables 66 - Figures 252 - Pages In this report, the peritoneal dialysis market has been segmented on the basis of offering, modality, disease indication, end user and region. The peritoneal dialysis market is segmented into peritoneal dialysis machines, solution bags, catheters, transfer sets, other peritoneal dialysis products and services on the basis of…
PR Newswire
04/10/2024

Ethypharm announces the appointment of Éric CHEVALIER as Group Human Resources…

Throughout his career, Éric Chevalier has held key positions in leading companies. In particular, he was Director of Human Resources at Biogen for 4 years, after having been HR Manager for several industrial organisations at General Electric Healthcare. He began his career at Coca-Cola Entreprises, where he spent nine years as an HR generalist. 20 years of experience have enabled him to acquire a comprehensive and integrated vision of HR, as well as solid expertise in the various key areas of…
PR Newswire
04/10/2024

Immatics Announces Upcoming Oral and Poster Presentations at the Society for…

Houston, Texas and Tuebingen, Germany, October 4, 2024–Immatics N.V.(NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming oral and poster presentations at the 39 thAnnual Meeting of the Society for Immunotherapy of Cancer in Houston, Texas from November 6 - 10, 2024. Full abstracts will be available on November 5, 2024, at 9:00 am EST in...
Nasdaq GlobeNewswire
04/10/2024

Cyient DLM Expands Global Footprint with Strategic Acquisition of US-Based EMS…

This acquisition is in line with Cyient DLM's strategic roadmap to expand geographic footprint, add strategic clients and increase client proximity. This acquisition is in line with Cyient DLM's strategic roadmap to expand geographic footprint, add strategic clients and increase client proximity. Krishna Bodanapu, Executive Chairman of Cyient DLM, commented, "This acquisition is a pivotal moment for Cyient DLM. It expands our global footprint, brings us closer to our strategic customers,...
PR Newswire
04/10/2024

Inside information: Bioretec updates its product development strategy by…

The acceleration of product development of the RemeOs™ Spinal Interbody Cage will have an effect on the company's overall product development strategy, and Bioretec's board of directors has updated the company's financial targets in line with the revised overall product development strategy. Information on the updated financial targets will be published in a separate company announcement. The acceleration of product development of the RemeOs ™Spinal Interbody Cage will have an effect on the...
PR Newswire
04/10/2024

Inside information: Bioretec updates its financial targets

Due to the acceleration of the product development of the RemeOs™ Spinal Interbody Cage, Bioretec's Board of Directors has today updated Bioretec's financial targets as follows: Due to the acceleration of the product development of the RemeOs™ Spinal Interbody Cage, Bioretec's Board of Directors has today updated Bioretec's financial targets as follows: The previously communicatedEUR 62 millionnet sales target and the timing of reaching cash flow positive stage from operating activities...
PR Newswire
04/10/2024

IM Cannabis Announces up to US$1,613,000 Private Placement Offering Led by…

Each Unit will be comprised of one Share and one Share purchase warrant (each, a "Warrant"). Each Warrant shall entitle the holder thereof to acquire one additional Share (each, a "Warrant Share) at a price equal to a 50% premium to the Offering Price (the "Warrant Exercise Price") at any time prior to 5:00 p.m. (Toronto time) on second anniversary of the closing date. The Offering, which is expected to close in one or more tranches, will be led by the Company's…
PR Newswire
04/10/2024

Piramal Pharma releases its Sustainability Report for FY 2023-24 under the…

Nandini Piramal, Chairperson of Piramal Pharma Ltd., said, "As we advance on our sustainability journey, we are deeply committed to transparency, accountability, and continuous improvement in our business practices. Our latest Sustainability Report not only highlights the milestones we've achieved but also demonstrates our capability to adapt to evolving global standards. By revising our Scope 1 and 2 GHG emissions and energy consumption for FY 2023, we have significantly improved data…
PR Newswire
04/10/2024

Clarivate in partnership with Abiquifi Announces Annual Summit LATAM Agenda

In the wake of the pandemic, the global pharmaceutical industry faced a slowdown in growth, prompting companies to swiftly identify new opportunities and areas of innovation. As the Latin American market is valued at $98 billion,1 with projected growth of 10.1%—outpacing North America (3.1%) and Europe (3.9%)—navigating this region is crucial for the future of the global pharmaceutical landscape. To maintain a competitive edge and ensure return on investment, organizations must adopt effective…
PR Newswire
04/10/2024

MD Logistics to Open State-of-the-art Dedicated Pharmaceutical Warehouse in…

NX Logo: https://kyodonewsprwire.jp/img/202409277148-O3-nAkv058x NX Logo:https://kyodonewsprwire.jp/img/202409277148-O3-nAkv058x Exterior view of warehouse:https://cdn.kyodonewsprwire.jp/prwfile/release/M103866/202409277148/_prw_PI1fl_PVWX1sAF.jpg Interior view of refrigerated warehouse:https://cdn.kyodonewsprwire.jp/prwfile/release/M103866/202409277148/_prw_PI2fl_3UA9VL4y.jpg Indianais known as the pharmaceutical manufacturing capital of the Midwest and is home to...
PR Newswire
04/10/2024

Orexo´s Nomination Committee for the Annual General Meeting 2025

The Nomination Committee will prepare proposals to the AGM regarding Chairman of the meeting, Chairman of the Board, Board members, Board member fees, any remuneration for committee work, and fees to the auditor, as well as principles for the composition of the Nomination Committee. The Nomination Committee will prepare proposals to the AGM regarding Chairman of the meeting, Chairman of the Board, Board members, Board member fees, any remuneration for committee work, and fees to the auditor…
PR Newswire
04/10/2024

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®…

Milan, 4 thOctober 2024– Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.Enjaymo® (sutimlimab) is a humanized monoclonal antibody indicated for the treatment of hemolysis in adults with CAD. In 2022, it was granted approval by the U.S. Food and Drug Administration...
Nasdaq GlobeNewswire
04/10/2024
Altri  Comunicati